Business
INVO Bioscience Advances Commercialization into the European Fertility Market with Initial Orders of INVOcell (IVC) in Spain
- Spain marks INVO's initial entry into the European market - Europe represents approximately 30% of the multi-billion dollar global fertility marketplace -
About this update from Invo Fertility, Inc.
[{"type":"text","content":"- Spain marks INVO's initial entry into the European market\n - Europe represents approximately 30% of the multi-billion dollar global fertility marketplace\n - The first three clinics in Spain have placed initial orders for INVOcell - an effective and affordable alternative treatment for patients diagnosed with infertility\n\n\nSARASOTA, Fla., Jan. 27, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced it has advanced its commercialization efforts into the European fertility market by securing initial orders of INVOcell in Madrid and Barcelona, Spain. INVOcell will initially be available at three separate existing fertility clinics which have placed orders and commenced training.\n\n \n \n \n \n \n \n\n \n\"We are excited to launch the commercialization of INVOcell into the European market, which represents a sizable portion of the overall global fertility market,\" commented Steve Shum, CEO of INVO Bioscience. \"With the advancement of our initial efforts in Spain, we plan to capitalize on this entry to further expand our activities both within Spain and across other European markets. We believe INVOcell offers patients and physicians a number of advantages, including the ability to provide the patient with a more connected experience and provide the clinic with a more efficient, less resource-consuming process, thereby enhancing capacity and providing an ability to treat more patients in need. With the CE-mark we received in late 2019, which we subsequently expanded to include 5-day labeling in 2020, INVOcell can now be launched into Europe. We are excited with our entry into Spain and these early adopting clinics which will help establish INVOcell's initial presence in the region.\" \nThe Company is working with a logistics provider to assist with all customs details relating to importing the INVOcell into the country and it will continue to evaluate distributor type relationships and joint venture opportunities to further expand INVOcell's presence throughout the region.\nSpain has a total population of approximately 47 million people. According to the World Bank, Spain has one of the lowest fertility ...